NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

That interview is a year old. Mostly what I heard was a plea for more patient level data and more trials using NWBO's Plll as a beginning point for EC's. She stressed needing more L product for more experiments / trials like they do with off label. No figures on Compassionate use which is pretty shocking that the question wasn't even asked. She stressed the Plll went from randomized to non randomized. LL said no FDA and didn't even mention MHRA.

On another note, I find it interesting that with enrollment being so difficult without the crossover option, that the FDA would step in at the last minute to halt enrollment. ??